



## GenSight Biologics announces its 2017 Financial Calendar

**Paris, France, 26 January 2017** – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced its schedule for the publication of financial information for 2017.

Event	Date*
2016 Q4 Cash Position	January 27, 2017
2017 Q1 Cash Position	April 26, 2017
2016 Full-Year Financial Update and Statements	April 27, 2017
Annual General Meeting	May 31, 2017
2017 First-Half Financial Update and Statements	July 28, 2017
2017 Q3 Cash Position	October 26, 2017
2017 Q4 Cash Position	January 25, 2018

*\*Subject to modification.*

### Contacts

#### GenSight Biologics

Thomas Gidoïn

Chief Financial Officer

[tgidoïn@gensight-biologics.com](mailto:tgidoïn@gensight-biologics.com)

+33 (0)1 76 21 72 20

#### RooneyPartners

Media Relations

Marion Janic

[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)

+1-212-223-4017

#### The Trout Group

Investor Relations

Chad Rubin

[crubin@troutgroup.com](mailto:crubin@troutgroup.com)

+1-646-378-2947

### About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics' lead product candidate, GS010, is in Phase III trials in Leber's Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.